Ramiro Ribeiro, M.D., Ph.D., serves as the Chief Medical Officer at EyePoint Pharmaceuticals Inc., a specialty pharmaceutical company focused on developing and commercializing treatments for eye diseases. Dr. Ribeiro brings a wealth of experience and expertise to his role, having spent over two decades in the field of ophthalmology and pharmaceutical development. He earned his medical degree and Ph.D. from the University of São Paulo in Brazil, where he also completed his residency in ophthalmology. Dr. Ribeiro's career has been marked by his dedication to advancing treatments for retinal diseases, and his leadership at EyePoint Pharmaceuticals is a testament to his commitment to improving patient outcomes. Prior to joining EyePoint Pharmaceuticals, Dr. Ribeiro held several key positions in the pharmaceutical industry, including roles at Alcon, Novartis, and Bausch + Lomb. At these companies, he was instrumental in the development and launch of several successful ophthalmic products, demonstrating his ability to navigate the complex landscape of drug development and regulatory approval. His work has contributed significantly to the field, particularly in the areas of diabetic macular edema and age-related macular degeneration. As Chief Medical Officer at EyePoint Pharmaceuticals, Dr. Ribeiro oversees the clinical development of the company's pipeline, ensuring that innovative treatments are brought to market efficiently and safely. His strategic vision and scientific acumen are vital to the company's mission of addressing unmet needs in ophthalmology.